Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.
Read Article
2026 Guidelines for the Treatment of Axial Spondyloarthritis
ACR
New and updated clinical guidelines released today provide comprehensive, evidence-based recommendations for the management of axial spondyloarthritis (axSpA) for both adults and children. The effort includes an update to the 2019 ACR/SAA/SPARTAN treatment guidelines focusing on adults,
Read Article
Late-Breaking Studies at EULAR 2026
MedPage Today
Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical
Read Article
In the psoriasis-to-PsA transition study at EULAR 2026, which ultrasound finding best distinguished progressing from stable subclinical PsA? Test your knowledge in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/kV0zA7qyg7
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow https://t.co/IhGQSxssyd
Links:
Nelly ZIADE 🍀 @Nellziade( View Tweet )
A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype
Results from the Spanish REGISPON-3
POS1352
#EULAR2026 @RheumNow https://t.co/XicguAdXJ1
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU?
Yes! POS 1347
Multicenter randomised open-label trial
N=56
#EULAR2026 @RheumNow https://t.co/kP7ropPkpC
Nelly ZIADE 🍀 @Nellziade( View Tweet )
LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
First head-to-head trial to show #PsA joint outcome superiority
BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%.
@RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD
Jiha Lee @JihaRheum( View Tweet )
#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN
Links:
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
LB0002: Sonelokimab (IL-17A/F Nanobody, ~40 kDa) in #axSpA Phase 2: 81% ASAS40 and 54% ASAS partial remission at 12 weeks. Mean ASDAS improvement of −2.0 from baseline. @RheumNow #EULAR2026 https://t.co/TjvtnFPCdj
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#OP0207 #EULAR2026: SUPERFIBRES trial suggests dietary fibre supplementation may enhance MTX response in RA. Inulin improved EULAR responses and Th17/Treg balance over 30 days, with strongest effects seen in MTX-treated patients. Fascinating microbiome-linked signal. @RheumNow https://t.co/nCvZlooamF
Mrinalini Dey @DrMiniDey( View Tweet )
Key messages in the tx of ax/p-SpA:
>csDMARDs only effective in pSpA
>consider individualized treatment for bDMARDs and JAKis
>Cycling TNFi equally effective to switching
@RheumNow #EULAR2026 https://t.co/oeO3BxmYYo
sheila @RHEUMarampa( View Tweet )
Not just ticking boxes!
Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA
What’s new?
Providing a stem so criteria will be applied only if w/SpA dx, not just imaging
MRI:active inflamm + structural lesions
Some SpA features omitted
@RheumNow #EULAR2026 https://t.co/NCV0EFvjYa
Links:
sheila @RHEUMarampa( View Tweet )
#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP.
At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+
POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr
sheila @RHEUMarampa( View Tweet )
Double targeted therapy in refractory SpA/PsA.
76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics.
Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit.
ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA):
81.6% (40/49) were in clinical remission
15 pts on drug-free remission
21 pts w/remission on meds still on GOL, no unSSAEs
Early aggressive tx is key!
AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt
Links:
sheila @RHEUMarampa( View Tweet )
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
🔥 TOGETHER-PsA (OP069) #EULAR2026 #EULARbest Ixekizumab + Tirzepatide vs IXE alone in PsA with obesity/overweight: ✅ Primary endpoint (ACR50 + ≥10% wt loss at W36): 31.7% vs. 0.8% (p<0.001) ✅ ACR50: 33.5% vs. 20.4% ✅ MDA: 26.3% vs. 15.3% (p=0.026) @rheumnow @DrLauraCoates https://t.co/6wh3S6khXw
Nelly ZIADE 🍀 @Nellziade( View Tweet )
🧬 Does spine vs knee enthesis differ immunologically?
Translational scRNAseq study: YES!
Spine produces more IL-23 but shows attenuated IL-17 response vs knee
#POS0084 #EULAR2026 @RheumNow https://t.co/itFrLEXSzZ
Nelly ZIADE 🍀 @Nellziade( View Tweet )
🎗️ Do targeted therapies raise cancer risk in SpA?
French nationwide cohort (n=56,591): NO
In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological.
#OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Recent Blogs
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do!
Read Post
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they?
Read Post
With the recent publication of the third iteration of the GRAPPA Psoriatic Arthritis (PsA) treatment recommendations, it seems to be an auspicious time to reflect on some key considerations that arose during the development of the recommendations, as well as to look towards what the future may hold.
Read Post
Podcasts
EULAR 2021 - Day2c00:37:25 -
EULAR 2021 - Day2b
00:35:57
